

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

**EP 0 845 267 A1**

(12)

**EUROPEAN PATENT APPLICATION**

(43) Date of publication:

**03.06.1998 Bulletin 1998/23**

(51) Int. Cl.<sup>6</sup>: **A61K 38/16**

(21) Application number: **96118958.6**

(22) Date of filing: **27.11.1996**

(84) Designated Contracting States:

**AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC  
NL PT SE**

(71) Applicant: **Binder, William J.**

**Pacific Palisades, California (US)**

(72) Inventor: **Binder, William J.**

**Pacific Palisades, California (US)**

(74) Representative:

**Patentanwälte**

**Schaad, Balass, Menz & Partner AG**

**Dufourstrasse 101**

**Postfach**

**8034 Zürich (CH)**

(54) **Neurotoxin for cutaneous disorders in mammals**

(57) A neurotoxin is used for the manufacture of a medicament for treatment of cutaneous cell-proliferative disorders in mammals. More specifically, the invention is useful in mitigating and inducing remission of lesions associated with such disorders and in controlling related symptoms of the disorders (such as scaling and itching). The medicament containing the invertebrate neurotoxin is administered to the skin of the host at or near the site of a lesion. The preferred neurotoxin for use in the invention is Botulinum toxin, particularly Botulinum toxin A.

**EP 0 845 267 A1**

## Description

## BACKGROUND OF THE INVENTION

## 1. Field of the Invention

The invention relates to the use of a neurotoxin for a medicament treating cutaneous cell-proliferative disorders in mammals, particularly psoriasis and dermatitis. More specifically, the invention relates to the use of a therapeutically effective and pharmaceutically safe neurotoxin, in particular Botulinum toxin A or Tetanus toxin.

## 2. History of the Prior Art

Psoriasis is a skin disorder which is believed to affect approximately 1.5% to 2% of the U.S. population with varying degrees of severity. Of this group, about 5% to 8% will also develop psoriatic arthritis, typically in peripheral joints.

Psoriasis is manifested by the development of lesions consisting of red patches of skin covered with whitish, pruritic scales. The lesions derive from a discrete increase in the normal number of basal cells of the epidermis. The cell population at the site of a lesion can turn over in about 3-4 days, compared to 27 days or more for normal skin. Psoriatic lesions may be comprised of elevated papules (papulosquamous lesions), reddish erosions (erythroderma) and/or pustules. Whatever their form, the lesions tend to be sharply demarcated, but can migrate from one location to another in the host skin. Typically, the lesions are formed on the skin of the arms, legs, elbows, knees, scalp or genitals where they may remain for period of several weeks to several months.

Although psoriasis is believed to have a genetic component, both its cause and cure are unknown. Thus, present treatments for psoriasis are directed toward controlling, rather than eliminating, the abnormally rapid proliferation of the epidermis which characterizes the disease. Since 1974, the most common method of treatment has been PUVA (psoralen ultraviolet A), wherein psoralen is given to sensitize the skin to ultraviolet light before the skin is exposed to ultraviolet light (A waves) for discrete periods of time to slow the production of new skin cells in affected areas.

In addition, 1,25-dihydroxyvitamin D<sub>3</sub> and nonhypercalcemic analogs thereof have recently been approved for use in topical preparations by the United States Food and Drug Administration for the treatment of psoriasis. Corticosteroids may also be given to address the itching and discomfort associated with psoriatic lesions.

Lesions similar to those which appear in the skin of patients suffering from psoriasis also appear in the skin of patients suffering from certain forms of dermatitis (eczema), including atopic and seborrheic dermatitis, as well as other less common cutaneous disorders, such as pityriasis rubra pilaris, pityriasis rosea and lichen simplex. Again, the cause of these non-contact dermatoses are largely unknown, although allergies and stress are believed to be related to the onset of lesion formation in many individuals. Corticosteroids and topical agents such as coal tar based ointments and shampoos are frequently applied to control the growth and spread of lesions.

The scaling and irritation which accompanies the formation of benign cutaneous lesions can also occur on formation of malignant lesions. Topical corticosteroids and emollients, though not curative of such lesions, can provide a measure of temporary relief of symptoms associated with the lesions for the patient.

Although topical use of vitamin D<sub>3</sub> is a promising new therapy for psoriasis, the range of treatment available for psoriasis and the symptoms of other cell-proliferative disorders of the skin is narrow and largely palliative in nature. A drawback shared by each available treatment is the need for frequent repetition, particularly of applications of topical corticosteroids. Cessation or interruption of treatment will often result in reappearance and even exacerbation of the patient's condition.

A need, therefore, exists for a treatment for skin lesions associated with cutaneous cell-proliferative disorders which is both effective and relatively long-lasting. To that end, the present invention provides a method for treating such skin lesions through administration to the skin (including the epidermal, dermal, subdermal and subcutaneous layers thereof) of a neurotoxin, in particular, Botulinum A.

Administration by injection of neurotoxins (such as invertebrate exotoxins) into or near muscle tissue has gained acceptance as a therapeutic modality for certain neuromuscular disorders. For example, serotype A of the Botulinum toxin (produced by *Clostridium botulinum*) has been recommended in the art for use for the treatment of certain diseases such as disorders of the extraocular muscles (e.g., comitant strabismus and nystagmus) as well as dystonias (involuntary contractions of facial muscle) (see, e.g., *The New England Journal of Medicine*, 324: 1186-1194, 1991). In this context, Botulinum toxin A is believed to produce a reversible, flaccid paralysis of mammalian skeletal muscle, presumably by blocking the exocytosis of acetylcholine at peripheral, presynaptic cholinergic receptors, with limited activity at receptors in the central nervous system (Rabasseda, et al., *Toxicon*, 26:329-326, 1988). Botulinum toxin A is not believed to result in degeneration of nervous or muscular tissue and has been approved for use in certain therapies by the U.S. Food and Drug Administration.

Other serotypes of the Botulinum toxin have been identified that have immunologically distinct phenotypes; i.e.,

serotypes B, C1, C2, D, F and G (Simpson, *et al.*, *Pharmacol.Rev.*, **33**:155-188, 1981). All of the serotypes are believed to be proteins of about 150 kDa molecular weight that are comprised of two polypeptide chains linked by disulphide bridges. The shorter of the two chains is believed to be responsible for the toxicity of the toxin, while the longer of the two chains is believed to be responsible for the penetration of the toxin into nervous tissue. Although antigenically different to some extent, the Botulinum serotypes are believed to be similar in their pharmacological actions (Brin, *et al.*, "Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology", *Neurology*, **40**:1332-1336, 1990).

In addition, like serotype A, serotypes B and E of the Botulinum toxin have been linked to cases of botulism in humans. Thus, having the same pathological activity as serotype A, serotypes B and E can be reasonably expected to have essentially the same biological activity as serotype A.

Other invertebrate toxins are known, or can reasonably be expected, to share the mode of action of Botulinum toxin. For example, serotypes A and E of the Botulinum toxin share a substantial degree of sequence homology with the Tetanus neurotoxin produced by *Clostridium tetani* (DasGupta, *et al.*, *Biochemie*, **71**:1193-1200, 1989). Further, although the tetanus neurotoxin typically acts on the central nervous system to produce rigid rather than flaccid muscle paralysis, at least one peptide digestion fragment of the tetanus toxin (fragment Ibc, which is produced as a papain cleavage product) have been shown to act peripherally to produce flaccid paralysis in a manner similar to botulinum toxin (Fedinic, *et al.*, *Boll. 1st. Sieroter Milan*, **64**:35-41, 1985; and, Gawade, *et al.*, *Brain Res.*, **334**:139-46, 1985).

Reversible, flaccid paralysis has also been observed following intrathecal injection of acylpolyamine toxins, anticholinergic, presynaptic neurotoxins that are produced in the venom of many invertebrates (Herold, *et al.*, *Anesthesiology*, **77**:507-512, 1992). In particular, two toxins (AR636 and AG489) from spiders *Argiope aurantia* and *Agelenopsis aperta* have been shown to produce motor inhibition at a dosage of 2 micrograms while 7 micrograms was an effective dosage to produce sensory inhibition.

Despite the apparent effects of such neurotoxins on motor and sensory activity in mammals, the use of such toxins in humans to date has been limited. In particular, such toxins have neither been used nor suggested for use to treat skin disorders such as psoriasis and dermatitis.

## SUMMARY OF THE INVENTION

The invention provides a medicament for treating cutaneous cell-proliferative disorders. Specifically, the invention comprises the use of therapeutically effective and pharmaceutically safe invertebrate presynaptic neurotoxin (hereafter, "neurotoxin") according to claim 1. The medicament will preferably be for subdermal or sub-cutaneous administration, but may also be for topical and transdermal routes of administration.

The preferred neurotoxin of the invention is Botulinum toxin A. Neurotoxins which are equivalent in pharmacology to Botulinum A are also suitable for use in the method of the invention.

A particular advantage of the invention is the relatively prolonged mitigation or remission of lesions in the treated area which may be achieved. For example, while relapse following cessation of corticosteroid or PUVA treatment may occur with a matter of days, affected areas treated according to the method of the invention may become and remain lesion free at the site of treatment for periods of several months.

## DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

### A. PRESYNAPTIC NEUROTOXIN COMPOSITIONS FOR USE IN THE METHOD OF THE INVENTION

The target tissue for administration of neurotoxin according to the invention is skin. "Skin" as used in this disclosure shall refer to the tissue comprised of epidermal, dermal, subdermal and subcutaneous layers of cells.

"Neurotoxin" as used in this disclosure refers to both invertebrate toxins and biologically active peptide fragments of proteinaceous invertebrate toxins. The neurotoxins of the invention will be those neurotoxins that exert a biological effect in mammals which is equivalent to the effect exerted by Botulinum toxin, particularly Botulinum toxin A.

In this respect, Botulinum toxin is known to produce reversible, flaccid paralysis of musculature in mammals on intramuscular injection but does not result in degeneration of muscle or nervous tissue. It is believed that this effect is the result of inhibition by Botulinum toxin of the release of acetylcholine from presynaptic vesicles of nerve endings. Other neurotoxins (e.g., Botulinum serotypes B and E) can be reasonably assumed to have similar modes of action to produce physiologically equivalent physiological responses.

The modality by which Botulinum toxin A achieves the effects described herein is unknown, but may be independent of its known activity (as an anticholinergic agent). However, it can be reasonably predicted that neurotoxins which possess biological activity similar to the known activity of Botulinum toxin A will also share in the latter's ability to reduce the number, severity and/or frequency of appearance of lesions on the skin of patients suffering from primary cutaneous disorders such as psoriasis and dermatitis (i.e., the "biological activity of the invention").

The preferred neurotoxin of the invention is botulinum toxin. Serotype A of this toxin is commercially available and is presently supplied by Allergan, Inc. of Irvine, California under the tradename "BOTOX" and by Porton Products Ltd, of the United Kingdom under the tradename "DYSPORT". A pentavalent toxoid of all eight known Botulinum serotypes is also available as an investigational drug from the U.S. Center for Disease Control in Atlanta, Georgia. Of these, the Botulinum A toxin preparations are most preferred for their known safety and efficacy.

Tetanus toxins for use as vaccines are also commercially available (from, for example, Lederle Laboratories of Wayne, New Jersey under the tradename "TETANUS TOXOID PUROGENATED"). As discussed above, the Ibc fragment of the Tetanus toxin is believed to act peripherally and is therefore likely to be similar in its activity to Botulinum toxin. Therefore, the method of the invention will preferably encompass the use of pharmaceutically safe forms of the Ibc fragment of the Tetanus toxin rather than the use of intact Tetanus toxin.

Those of ordinary skill in the art will know, or can readily ascertain, how to obtain the neurotoxins of the invention, including the Botulinum and Tetanus toxins, in a pharmaceutically safe form; preferably, a form that is nonteratogenic and does not induce a detectable immune response to the toxin antigen. For most of the neurotoxins of the invention, pharmaceutical safety will be dose-dependent such that relatively low dosages of toxin will be "safe" as compared to dosages which are known to be sufficient to produce disease.

Preferably, the neurotoxins of the invention will be administered as a composition in a pharmaceutically acceptable carrier. To that end, presynaptic neurotoxin compositions are prepared for administration by mixing a toxin the desired degree of purity with physiologically acceptable sterile carriers. Such carriers will be nontoxic to recipients at the dosages and concentrations employed. Ordinarily, the preparation of such compositions entails combining the neurotoxin with buffers, antioxidants such as ascorbic acid, low molecular weight (less than about 10 residues) polypeptides, proteins, amino acids, carbohydrates including glucose or dextrans, chelating agents such as EDTA, glutathione and other stabilizers and excipients. Such compositions may also be lyophilized and will be pharmaceutically acceptable, i.e., suitably prepared and approved for use in the desired application.

For transdermal and topical administration, the neurotoxin will preferably be formulated to enhance penetration of the neurotoxin to and across the stratum corneum of the skin. Those of ordinary skill in the art will be familiar with, or can readily ascertain the identity of, excipients and additives which will facilitate drug delivery (particularly of peptides) across skin. For review in this respect, reference may be made to *"Novel Drug Delivery Systems"*; Chien, ed. (Marcel Dekker, 1992), the disclosure of which is incorporated herein by this reference to illustrate the state of knowledge in the art concerning drug delivery to and across the stratum corneum of skin.

Most preferably, the neurotoxin will be formulated in unit dosage form for ease of administration. For example, the neurotoxin may be supplied as a sterile solution or lyophilized powder in a vial.

## B. METHODS FOR ADMINISTRATION OF THE NEUROTOXINS

Generally, the dose of presynaptic neurotoxin to be administered will vary with the age, presenting condition and weight of the host to be treated. Suitable candidates for treatment according to the method of the invention will be persons suffering from cutaneous cell-proliferative disorders; i.e., disorders of the skin which include as symptoms the development of lesions. In this respect, "lesions" shall mean a population of cells which has undergone, or is predisposed to undergo, an abnormally high rate of cellular growth. Predisposition to such growth may be determined according to conventional clinical standards, such as a prior or contemporaneous diagnosis or family history of a cutaneous cell-proliferative disorder (e.g., psoriasis, dermatitis, and forms of pityriasis, such as pityriasis rosea, pityriasis rosacea and pityriasis rubra).

The potency of the neurotoxin will also be considered. Toxin potency is expressed as a multiple of the LD<sub>50</sub> value for a reference mammal, usually a mouse. Where a mouse is the reference mammal, one "unit" of toxin is the amount of toxin that kills 50% of a group of mice that were disease-free prior to inoculation with the toxin. For example, commercially available Botulinum toxin A typically has a potency such that one nanogram contains about 40 mouse units. The potency in humans of the Botulinum toxin A product supplied by Allergan, Inc. under the registered trademark "BOTOX" is believed to be about LD<sub>50</sub>=2,730 units.

Assuming a potency which is substantially equivalent to LD<sub>50</sub>=2,730 units, the neurotoxin can be administered in a dose of up to about 1000 units, although individual dosages of about 5-15 units are preferred while dosages of as low as about 2 to 5 units will have therapeutic efficacy and are particularly preferred for initial treatments and treatments where the neurotoxin is applied to more than one lesion or area at a time. The dosage may also be adjusted upward or downward depending on the size of each lesion to be treated. Generally, the neurotoxin will be administered as a composition at a dosage that is proportionally equivalent to about 2.5 cc/100 units. Those of ordinary skill in the art will know, or can readily ascertain, how to adjust these dosages for neurotoxins of greater or lesser potency.

Preferably, the lowest therapeutically effective dosage (i.e., the dosage which results in detection by the patient of a reduction in the occurrence, number and/or severity of skin lesions and associated discomfort experienced by the patient) will be administered. In the initial treatment, a low dosage may be administered at one site to determine the

patient's sensitivity to, and tolerance of, the neurotoxin. Additional injections of the same or different dosages will be administered as necessary.

In this respect, although the mechanism of action by which the method of the invention achieves therapeutic benefits is unknown, it is possible that the neurotoxin administered according to the invention causes a slowing of the growth cycle of cells at the affected site. If this prediction is accurate, then the relative efficacy of treatment may depend on whether the cells to be treated are in a phase of growth which is most susceptible to modulation; i.e., during DNA synthesis. Thus, the efficacy of the method of treatment of the invention will likely be enhanced by repeating the treatment at a later time when the cells to be treated are likely to be undergoing a different phase of growth. The need for such repetition can be determined by gauging whether the treated lesions have reduced in size, improved in appearance, or gone into remission within about 7 to 10 days after treatment.

For many indications, subcutaneous or subdermal injection at the site of a lesion or at a region of skin affected by lesions will be the most efficacious route of administration. Preferably, the injection will be provided to the subcutaneous or subdermal region beneath the lesion by inserting the needle under the lesion from its side. However, where the lesion is too large or otherwise not susceptible to this approach, the injection can be provided through the lesion to the underlying layers of skin. Alternatively, the neurotoxin may be administered by transdermal or topical routes at the site of one or more lesions. However, it is expected that these latter routes will be less efficacious than subcutaneous or subdermal injection and may, therefore, be best used for subacute manifestations.

The injections will be repeated as necessary. As a general guideline, it has been observed that, after administration of Botulinum toxin A into or near lesions in adult human skin according to the method of the invention, the treated site has remained lesion free for periods of at least 2 months. However, Botulinum A toxin in particular is expected to be most effective when administered according to the method of the invention soon after the appearance of any new lesions. Depending on the course of therapy applied (i.e., with respect to dosage, frequency of treatment and sensitivity of individual patients to treatment), the method of the invention can be expected to be effective in mitigating lesions (e.g., by reducing their size or incidence), inducing remission of the disorder (e.g., by eliminating existing lesions), and in controlling symptoms associated with the disorder (e.g., scaling of lesions and itching).

The invention having been fully described, examples illustrating its practice are set forth below. These examples should not, however, be considered to limit the scope of the invention, which is defined by the appended claims.

In the examples, the abbreviation "min" refers to minutes, "hrs" and "h" refer to hours, "mo" and "mos" refers to months, "yr" and "yrs" refer to years, and measurement units (such as "ml") are referred to by standard abbreviations. "Cm." refers to the diameter of each lesion described. "Remission" refers to the complete disappearance of a lesion, while "mitigation" refers to a reduction in the size of a lesion. "F" refers to female and "M" refers to male. All dosages were of BOTOX® and were administered by subcutaneous injection unless otherwise indicated.

#### **EXAMPLE 1**

##### **ADMINISTRATION OF BOTULINUM TOXIN A TO TREAT SKIN LESIONS ASSOCIATED WITH CUTANEOUS CELL-PROLIFERATIVE DISORDERS**

7 adult, human patients received subcutaneous and/or subdermal injections of Botulinum toxin A ("BOTOX®"), reconstituted with saline to a concentration of 2.5 cc/100 units. The toxin was administered at sites where at least one lesion was present on the patient's skin.

Additional details of the case history, treatment, and post-treatment history of patients within the headache group who agreed to provide such information are tabulated below in Table 1.

TABLE 1

Age/ Sex	Presenting Condition	Prior Treatment	Site of Lesion(s)/ Delivery	Dosage and Frequency of Injection	Post Injection Condition
34/M	Chronic psoriasis. Lesions typically appear and heal in about a 45 day cycle.	Topical and systemic corticosteroids; PUVA.	2.5 cm. lesion, right leg.	2 units on 8/26/94.	Lesion in remission by 9/1/94. Had not returned by 12/94.

Age/ Sex	Presenting Condition	Prior Treatment	Site of Lesion(s)/ Delivery	Dosage and Frequency of Injection	Post Injection Condition
58/M	Dermatitis (severe eczema) as a child. Chronic psoriasis as an adult.	Topical and systemic corticosteroids; sunlight, bleach, abrasion of lesions.	Right elbow (2 lesions @ 2-3 cm.); left elbow (2 lesions @ 2-4 cm.); right ankle (1 lesion @ 10-12 cm.)	Right elbow: 5 units. Left elbow: 3 units. Right ankle: 5 units. Administered in 10/94.	Right elbow: lesion in remission within about 1 week. Left elbow: mitigated to nearly 100% in same period. Right ankle: mitigated to nearly 100% in one week. No return of lesions at right elbow by 12/94; lesions at other sites had not increased in size or severity by 12/94.

Age/ Sex	Presenting Condition	Prior Treatment	Site of Lesion(s)/ Delivery	Dosage and Frequency of Injection	Post Injection Condition
62/F	Severe eczema from childhood.	Topical emollients and corticosteroids.	3 lesions on the left arm (@2-5 cm.)	5 units at site of one 2 cm. lesion on 10/5/94.	Treated lesion in remission within 6 days. Some mitigation observed of untreated lesions. By 12/94, treated lesion had not returned and no new lesions had developed in the surrounding area.
42/M	Seborrheic dermatitis and psoriasis (latter for 10 years)	Topical and systemic corticosteroids.	Scalp: one 1.5 cm. lesion.	5 units at site of lesion on 11/7/94.	Lesion in remission within 5 days. Had not returned by 12/94.



Age/ Sex	Presenting Condition	Prior Treatment	Site of Lesion(s)/ Delivery	Dosage and Frequency of Injection	Post Injection Condition
31/M	Seborrheic dermatitis and psoriasis.	Salicylic acid, fluonoline cream; topical clobetasol propionate.	Scalp: one 3 cm. lesion. Postauricular area (ear): one 2 cm. lesion.	10 units at site of scalp lesion. 7 units at site of postauricular lesion. Both injections on 10/31/94.	Scalp lesion mitigated about 25% after 3 days. By 12/94, mitigated to nearly 100%. Postauricular lesion was about 70% mitigated after 6 weeks.
52/F	Mild psoriasis until age 30; severe psoriasis thereafter.	Topical and systemic corticosteroids; PUVA.	Right elbow: one 3 cm. lesion.	7 units at the site of the elbow lesion on 11/21/94.	Lesion in remission by 12/94.
44/M	Psoriasis; eczema and pyriatis rosea.	Emollients, salicylic acid and tar shampoos.	One lesion on forehead (@ 1.5 cm.)	10 units at site of lesion on 12/5/94.	Itching at site of lesion stopped within 3 days; scaling reduced within 5 days. Lesion almost entirely mitigated within 2 weeks.

Claims

1. Use of a neurotoxin for the manufacture of a medicament treating cutaneous cell-proliferative disorders in mammals.
2. Use according to claim 1, wherein the neurotoxin is Botulinum toxin.
3. Use according to claim 2, wherein the Botulinum toxin is Botulinum toxin A.
4. Use according to claim 1, wherein the neurotoxin is a biologically active fragment of a Tetanus toxin.
5. Use according to claim 4, wherein the biologically active fragment of Tetanus toxin is the Ibc fragment.
6. Use according to one of the preceeding claims for the manufacture of a medicament for administration by subcutaneous injection.
7. Use according one of the claims 1 to 5 for the manufacture of a medicament for delivery to the site of the lesion.
8. Use according to claim 1 for the manufacture of a medicament for controlling symptoms associated with the onset or presence of a cutaneous cell-proliferative disorder in a mammal to be delivered to the mammal skin.
9. Use according to claim 8, wherein the neurotoxin is Botulinum toxin.
10. Use according to claim 8, wherein the neurotoxin is Tetanus toxin.



European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number  
EP 96 11 8958

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
A	WO 94 28923 A (ALLERGAN INC.) * claims 1-25 *	1-10	A61K38/16
A	--- JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, vol. 34, no. 4, April 1996, pages 788-797, XP000197326 A. CARRUTHERS ET AL: "Botulinum A exotoxin use in clinical dermatology" * page 791, left-hand column, line 19 - page 793, left-hand column, line 8 *	1-10	
A	--- JOURNAL OF NEUROLOGY, vol. 239, 1 January 1992, pages 16-20, XP002009346 P. HAMBLETON : "Clostridium botulinum toxins: a general review of involvement in disease, structure, mode of action and preparation for clinical use" * page 17, right-hand column, last paragraph - page 18, right-hand column, line 5 *	1-10	
A	--- MICROBIOLOGICAL REVIEWS, vol. 56, no. 1, March 1992, USA, pages 80-99, XP000569909 E. J. SCHANTZ ET AL: "Properties and Use of Botulinum Toxin and Other Microbial Neurotoxins in Medicine" * page 83, right-hand column, line 60 - page 85, left-hand column, line 29 *	1-10	
	--- -/--		
The present search report has been drawn up for all claims			
Place of search BERLIN		Date of completion of the search 16 April 1997	Examiner Siatou, E
<p><b>CATEGORY OF CITED DOCUMENTS</b></p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons ----- &amp; : member of the same patent family, corresponding document</p>			

EPO FORM 1503 01.92 (P04C01)



European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number  
EP 96 11 8958

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
A	ACTA DERMATOVENEREOLOGICA, vol. 75, no. 1, January 1995, pages 434-436, XP000197303 M. VOGELSANG ET AL: "acetylcholine Induces Different Cutaneous Sensations in Atopic and Non-atopic Subjects" * page 435, left-hand column, last paragraph - page 436, left-hand column, line 23 * -----	1-10	
			TECHNICAL FIELDS SEARCHED (Int.Cl.6)
The present search report has been drawn up for all claims			
Place of search BERLIN		Date of completion of the search 16 April 1997	Examiner Siatou, E
<b>CATEGORY OF CITED DOCUMENTS</b> X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons ----- & : member of the same patent family, corresponding document			

EPO FORM 1503 03.82 (P04C01)